Global pharma major Lupin has reached an agreement with Unitaid, The Aurum Institute, the Clinton Health Access Initiative (CHAI), and other global procurement agencies to support tuberculosis (TB) prevention treatment that will be rolled out to 138 countries, including many low-and middle-income countries with a large burden of TB.

Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price.

As a global leader in anti-TB medicines, Lupin is committed to ensuring its products are widely available in all countries and there is equitable access to treatment globally. 

“We are glad to partner on these important products as this closely aligns with our mission of building better health, globally. Through this, we will further reinforce our long legacy to provide shorter, more patient-friendly treatment options to prevent TB,” said Nilesh Gupta, Managing Director, Lupin.

“Lupin continues its accelerated efforts in line with WHO’s The End TB Strategy program. Our expertise in fermentation-based products and backward integration for Rifapentine, enables us to be in a unique position to provide affordable, quality TB prevention and treatment options, and save lives globally,” said Naresh Gupta, President – API and Global Institution Business, Lupin.